O	0	6	Impact
O	7	9	of
O	10	11	a
B-intervention	12	19	topical
I-intervention	20	26	lotion
I-intervention	26	27	,
I-intervention	28	33	CG428
O	33	34	,
O	35	37	on
O	38	47	permanent
O	48	60	chemotherapy
O	60	61	-
O	61	68	induced
O	69	77	alopecia
O	78	80	in
O	81	87	breast
O	88	94	cancer
O	95	104	survivors
O	104	105	:
O	106	107	a
O	108	113	pilot
O	114	124	randomized
O	125	131	double
O	131	132	-
O	132	137	blind
O	138	148	controlled
O	149	157	clinical
O	158	163	trial
O	164	165	(
O	165	171	VOLUME
O	172	175	RCT
O	175	176	)
O	176	177	.

O	178	182	This
O	183	188	study
O	189	194	aimed
O	195	197	to
O	198	206	evaluate
O	207	210	the
O	211	217	impact
O	218	220	of
O	221	222	a
O	223	230	topical
O	231	237	lotion
O	238	239	(
O	239	244	CG428
O	244	245	)
O	246	248	on
O	249	253	hair
O	254	263	thickness
O	264	267	and
O	268	275	density
O	276	278	in
O	279	285	breast
O	286	292	cancer
O	293	302	survivors
O	303	307	with
O	308	317	permanent
O	318	330	chemotherapy
O	330	331	-
O	331	338	induced
O	339	347	alopecia
O	348	349	(
O	349	353	PCIA
O	353	354	)
O	354	355	.

O	356	359	The
O	360	365	study
O	366	369	was
O	370	371	a
O	372	378	double
O	378	379	-
O	379	384	blind
O	384	385	,
O	386	396	randomized
O	397	407	controlled
O	408	413	trial
O	414	419	which
O	420	429	conducted
O	430	434	from
O	435	443	February
O	444	448	2016
O	449	451	to
O	452	460	December
O	461	465	2016
O	466	468	at
O	469	472	the
O	473	480	Samsung
O	481	494	Comprehensive
O	495	501	Cancer
O	502	508	Center
O	509	511	in
B-location	512	517	Seoul
I-location	517	518	,
I-location	519	524	South
I-location	525	530	Korea
O	530	531	.

B-eligibility	532	538	Breast
I-eligibility	539	545	cancer
I-eligibility	546	554	patients
I-eligibility	555	559	with
I-eligibility	560	564	PCIA
O	565	569	were
O	570	580	randomized
O	581	583	on
O	584	591	average
O	592	594	of
O	595	596	3
O	596	597	.
O	597	598	5
O	599	604	years
O	605	610	after
O	611	623	chemotherapy
O	623	624	.

O	625	632	Topical
O	633	639	lotion
O	640	641	(
O	641	646	Batch
O	647	652	DT023
O	652	653	)
O	654	656	is
O	657	658	a
O	659	668	botanical
O	669	673	drug
O	674	679	under
O	680	691	development
O	692	702	containing
O	703	704	a
O	705	710	novel
O	711	719	patented
O	720	725	blend
O	726	728	of
O	729	730	4
O	731	740	botanical
O	741	752	ingredients
O	752	753	:
O	754	760	citrus
O	760	761	,
O	762	767	cocoa
O	767	768	,
O	769	776	guarana
O	776	777	,
O	778	781	and
O	782	787	onion
O	787	788	.

O	789	801	Participants
O	802	806	were
O	807	812	asked
O	813	815	to
O	816	820	self
O	820	821	-
O	821	826	apply
O	827	830	the
O	831	836	study
O	837	844	product
O	845	847	or
B-control	848	855	placebo
O	856	861	twice
O	862	865	per
O	866	869	day
O	870	873	for
O	874	875	6
O	876	882	months
O	882	883	.

O	884	891	Changes
O	892	894	in
O	895	899	hair
O	900	907	density
O	908	911	and
O	912	921	thickness
O	922	926	were
O	927	935	assessed
O	936	941	using
O	942	943	a
O	944	955	noninvasive
O	956	970	bioengineering
O	971	977	device
O	977	978	,
O	979	982	and
O	983	990	patient
O	990	991	-
O	991	999	reported
O	1000	1008	outcomes
O	1009	1013	were
O	1014	1023	evaluated
O	1024	1026	at
O	1027	1028	3
O	1029	1032	and
O	1033	1034	6
O	1035	1041	months
O	1042	1047	after
O	1048	1061	randomization
O	1061	1062	.

O	1063	1064	A
O	1065	1070	total
O	1071	1073	of
B-total-participants	1074	1076	35
O	1077	1085	patients
O	1086	1090	were
O	1091	1101	randomized
O	1102	1104	to
O	1105	1117	intervention
O	1118	1119	(
O	1119	1120	N
O	1121	1122	=
B-intervention-participants	1123	1125	18
O	1125	1126	)
O	1127	1129	or
O	1130	1137	placebo
O	1138	1139	(
O	1139	1140	N
O	1141	1142	=
B-control-participants	1143	1145	17
O	1145	1146	)
O	1146	1147	.

O	1148	1156	Patients
O	1157	1159	in
O	1160	1163	the
O	1164	1176	intervention
O	1177	1182	group
O	1183	1187	were
O	1188	1193	older
O	1194	1198	than
O	1199	1204	those
O	1205	1207	in
O	1208	1211	the
O	1212	1219	placebo
O	1220	1225	group
O	1226	1227	(
B-age	1227	1229	52
I-age	1229	1230	.
I-age	1230	1231	1
I-age	1232	1234	vs
I-age	1234	1235	.
I-age	1236	1238	41
I-age	1238	1239	.
I-age	1239	1240	6
I-age	1241	1246	years
O	1246	1247	;
O	1248	1249	P
O	1250	1251	<
O	1252	1253	0
O	1253	1254	.
O	1254	1257	001
O	1257	1258	)
O	1258	1259	.

O	1260	1263	The
B-outcome	1264	1268	mean
I-outcome	1269	1273	hair
I-outcome	1274	1281	density
I-outcome	1282	1283	(
I-outcome	1283	1285	SD
I-outcome	1285	1286	)
I-outcome	1287	1289	at
I-outcome	1290	1298	baseline
O	1299	1302	was
B-iv-cont-mean	1303	1305	97
I-iv-cont-mean	1305	1306	.
I-iv-cont-mean	1306	1307	6
O	1308	1309	(
B-iv-cont-sd	1309	1310	6
I-iv-cont-sd	1310	1311	.
I-iv-cont-sd	1311	1312	4
O	1312	1313	)
O	1314	1317	and
B-cv-cont-mean	1318	1321	126
I-cv-cont-mean	1321	1322	.
I-cv-cont-mean	1322	1323	8
O	1324	1325	(
B-cv-cont-sd	1325	1327	30
I-cv-cont-sd	1327	1328	.
I-cv-cont-sd	1328	1329	3
O	1329	1330	)
O	1331	1336	hairs
O	1336	1337	/
O	1337	1340	cm2
O	1341	1343	in
O	1344	1347	the
O	1348	1360	intervention
O	1361	1364	and
O	1365	1372	placebo
O	1373	1378	group
O	1378	1379	,
O	1380	1392	respectively
O	1393	1394	(
O	1394	1395	P
O	1396	1397	=
O	1398	1399	0
O	1399	1400	.
O	1400	1403	005
O	1403	1404	)
O	1404	1405	.

O	1406	1409	The
O	1410	1423	corresponding
O	1424	1430	values
O	1431	1434	for
B-outcome	1435	1439	hair
I-outcome	1440	1449	thickness
O	1450	1454	were
B-iv-cont-mean	1455	1457	49
I-iv-cont-mean	1457	1458	.
I-iv-cont-mean	1458	1459	9
O	1460	1461	(
B-iv-cont-sd	1461	1463	12
I-iv-cont-sd	1463	1464	.
I-iv-cont-sd	1464	1465	7
O	1465	1466	)
O	1467	1470	and
B-cv-cont-mean	1471	1473	48
I-cv-cont-mean	1473	1474	.
I-cv-cont-mean	1474	1475	1
O	1476	1477	(
B-cv-cont-sd	1477	1478	8
I-cv-cont-sd	1478	1479	.
I-cv-cont-sd	1479	1480	4
O	1480	1481	)
O	1482	1483	Î¼
O	1483	1484	m
O	1484	1485	,
O	1486	1498	respectively
O	1498	1499	.

O	1500	1505	After
B-outcome	1506	1507	6
I-outcome	1508	1514	months
O	1514	1515	,
B-outcome	1516	1520	hair
I-outcome	1521	1528	density
O	1529	1532	had
O	1533	1542	increased
O	1543	1545	by
B-iv-cont-mean	1546	1548	34
I-iv-cont-mean	1548	1549	.
I-iv-cont-mean	1549	1550	7
O	1551	1554	and
B-cv-cont-mean	1555	1557	24
I-cv-cont-mean	1557	1558	.
I-cv-cont-mean	1558	1559	9
I-cv-cont-mean	1559	1560	%
O	1561	1569	compared
O	1570	1574	with
O	1575	1583	baseline
O	1584	1586	in
O	1587	1590	the
O	1591	1603	intervention
O	1604	1607	and
O	1608	1615	control
O	1616	1622	groups
O	1622	1623	,
O	1624	1636	respectively
O	1637	1638	(
O	1638	1639	P
O	1640	1641	=
O	1642	1643	0
O	1643	1644	.
O	1644	1646	37
O	1646	1647	)
O	1647	1648	.

O	1649	1662	Corresponding
O	1663	1669	values
O	1670	1673	for
B-outcome	1674	1678	hair
I-outcome	1679	1688	thickness
O	1689	1693	were
B-iv-cont-mean	1694	1696	19
I-iv-cont-mean	1696	1697	.
I-iv-cont-mean	1697	1698	8
O	1699	1702	and
B-cv-cont-mean	1703	1705	35
I-cv-cont-mean	1705	1706	.
I-cv-cont-mean	1706	1707	6
I-cv-cont-mean	1707	1708	%
O	1708	1709	,
O	1710	1722	respectively
O	1723	1724	(
O	1724	1725	P
O	1726	1727	=
O	1728	1729	0
O	1729	1730	.
O	1730	1732	23
O	1732	1733	)
O	1733	1734	.

O	1735	1742	Similar
O	1743	1751	findings
O	1752	1756	were
O	1757	1765	observed
O	1766	1771	after
O	1772	1775	age
O	1776	1786	adjustment
O	1786	1787	.

O	1788	1790	In
O	1791	1795	this
O	1796	1801	pilot
O	1802	1812	randomized
O	1813	1821	clinical
O	1822	1827	trial
O	1827	1828	,
O	1829	1831	we
O	1832	1840	observed
O	1841	1847	safety
O	1847	1848	,
O	1849	1861	tolerability
O	1861	1862	,
O	1863	1866	and
O	1867	1868	a
O	1869	1874	trend
O	1875	1881	toward
O	1882	1885	the
O	1886	1894	efficacy
O	1895	1897	of
O	1898	1903	CG428
O	1904	1906	vs
O	1906	1907	.
O	1908	1915	placebo
O	1915	1916	,
O	1917	1927	especially
O	1928	1937	regarding
O	1938	1942	hair
O	1943	1950	density
O	1951	1954	and
O	1955	1959	self
O	1959	1960	-
O	1960	1968	reported
O	1969	1980	improvement
O	1980	1981	.
